H. Lundbeck, Azilect® (rasagiline) recommended for approval in the EU

H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. announced today that the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Azilect® (rasagiline) for the treatment of Parkinson's disease both as initial monotherapy in patients with early Parkinson’s disease (PD) and as adjunct treatment in moderate-to-advanced disease.